# Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/amivantamab-plus-lazertinib-versus-osimertinib-in-first-line-egfr-mutant/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Enriqueta Felip,Byoung Chul Cho,V. Gutiérrez,Adlinda Alip,Benjamin Besse,Shaolin Lü,Alexander I. Spira,N. Girard,Raffaele Califano,S.M. Gadgeel,James Chih‐Hsin Yang,Sadamu YAMAMOTO,K. Azuma,Yu Jung Kim,K.-H. Lee,Pongwut Danchaivijitr,C.G. Ferreira,Yun Cheng,Mehmet Alı Nahıt Şendur,G.-C. Chang,C.-C. Wang,K. Prabhash,Y. Shinno,Daniil Stroyakovskiy,L. Paz-Ares,Jerónimo Rafael Rodríguez‐Cid,Claire Martin,M.R. García Campelo,H. Hayashi,Danny Nguyen,P. Tomasini,Maya Gottfried,Christophe Dooms,Antonio Passaro,Martin Schüler,A.C.Z. Gelatti,Scott Owen,K. Perdrizet,S.-H.I. Ou,J.C. Curtin,J. Zhang,Michael Gormley,Tingting Sun,Amey C Panchal,Marguerite Ennis,E. Fennema,Mahesh Daksh,Seema Sethi,J.M. Bauml,S.-H. Lee |
| Citations | 85 |
| DOI | 10.1016/j.annonc.2024.05.541 |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | true |
| OA Status | hybrid |
| OA URL | https://doi.org/10.1016/j.annonc.2024.05.541 |
| OpenAlex ID | https://openalex.org/W4400029468 |
| PMID | 38942080 |
| Type | article |
| Year | 2024 |

## Paper authors

- [Adlinda Alip](https://scholariq.org/researchers/adlinda-alip/)

## Paper journal

- [Annals of Oncology](https://scholariq.org/journals/annals-of-oncology/)

## Paper primary topic

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

## Paper topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.